Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 1
1996 3
1998 1
1999 2
2000 1
2001 2
2002 1
2005 2
2006 1
2007 2
2008 2
2009 1
2010 4
2011 4
2012 4
2013 1
2014 2
2015 1
2018 1
2019 4
2020 4
2021 8
2022 4
2023 6
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. Giovannoni G, et al. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089960 Free article. Clinical Trial.
Editorial: Cytokines and CNS diseases.
Balabanov R. Balabanov R. Front Cell Neurosci. 2023 Nov 27;17:1335455. doi: 10.3389/fncel.2023.1335455. eCollection 2023. Front Cell Neurosci. 2023. PMID: 38089144 Free PMC article. No abstract available.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Differential Diagnosis of Tumor-like Brain Lesions.
Perez Giraldo GS, Singer L, Cao T, Jamshidi P, Dixit K, Kontzialis M, Castellani R, Pytel P, Anadani N, Bevan CJ, Grebenciucova E, Balabanov R, Cohen BA, Graham EL. Perez Giraldo GS, et al. Among authors: balabanov r. Neurol Clin Pract. 2023 Oct;13(5):e200182. doi: 10.1212/CPJ.0000000000200182. Epub 2023 Aug 30. Neurol Clin Pract. 2023. PMID: 37664132 Free PMC article. Review.
Treatment of natalizumab-associated PML with filgrastim.
Stefoski D, Balabanov R, Waheed R, Ko M, Koralnik IJ, Sierra Morales F. Stefoski D, et al. Among authors: balabanov r. Ann Clin Transl Neurol. 2019 Apr 8;6(5):923-931. doi: 10.1002/acn3.776. eCollection 2019 May. Ann Clin Transl Neurol. 2019. PMID: 31139690 Free PMC article.
Can Immune Tolerance Be Re-established in Neuromyelitis Optica?
Loda E, Arellano G, Perez-Giraldo G, Miller SD, Balabanov R. Loda E, et al. Among authors: balabanov r. Front Neurol. 2021 Dec 20;12:783304. doi: 10.3389/fneur.2021.783304. eCollection 2021. Front Neurol. 2021. PMID: 34987468 Free PMC article. Review.
66 results